Efficacy of postoperative antiviral combined transcatheter arterial chemoembolization therapy in prevention of hepatitis B-related hepatocellular carcinoma recurrence

被引:0
|
作者
YAN Qiang [1 ,2 ]
NI Jun [2 ]
ZHANG Guo-lei [2 ]
YAO Xing [2 ]
YUAN Wen-bin [2 ]
ZHOU Lin [1 ]
ZHENG Shu-sen [1 ]
机构
[1] Division of Hepatobiliary and Pancreatic Surgery,First Affiliated Hospital,Zhejiang University School of Medicine
[2] Department of Hepatobiliary and Pancreatic Surgery,Huzhou Central Hospital
关键词
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
Background Recurrence of hepatitis B-related hepatocellular carcinoma(HCC) after curative resection is the leading factor influencing the prognosis of the disease.Therefore,further improvement of long-term survival may depend on the prevention and treatment of the recurrent tumor.The aim of this research was to investigate the role of antiviral therapy and postoperative transcatheter arterial chemoembolization(TACE) in the prevention and treatment of hepatitis B-related HCC recurrence.Methods One hundred and twenty patients who underwent curative resection of hepatitis B-related HCC between January 2005 and June 2008 at our hospital were enrolled.Patients were divided into four groups according to the post-operative adjuvant therapy they received,i.e.,control,antiviral therapy group,TACE group,and combined group.The disease-free survival(DFS) and the 12-,24-,36-month cumulative recurrence rates were studied.Results There was no significant difference between isolated postoperative antiviral therapy group and control in terms of disease-free survival(P=0.283),while it was significantly higher in the TACE group compared to control(P=0.019).In all patients,however,viral prophylactic therapy combined with/without TACE brought a favorable result compared to those only with/without TACE(P <0.001).Similarly,no matter combined with or without antiviral treatment,postoperative TACE prolonged DFS(P=0.015).Naturally,a combination of viral prophylactic therapy on the baseline TACE significantly benefited patients’ postoperative DFS(P=0.047) and vice verse(P=0.002).The 24-month cumulative recurrence rates of combined group were significantly lower than that of isolated control group and antiviral therapy(P<0.001 and P=0.011respectively).However,36-month recurrence rate was significantly different in the control group compared to the TACE group and combined group(P=0.040 and 0.002 respectively);same as the antiviral group compared to the combined group(P=0.034).Conclusions Post-operative TACE prevents early recurrence while antiviral therapy prevents late recurrence of HCC.Combination of antiviral therapy and TACE are suggested for prevention in HCC patients with high risk of recurrence.
引用
收藏
页码:855 / 859
相关论文
共 50 条
  • [41] Risk of recurrence in hepatitis B-related hepatocellular carcinoma: Impact of viral load in late recurrence
    Hoshida, Yujin
    JOURNAL OF HEPATOLOGY, 2009, 51 (05) : 842 - 844
  • [42] Efficacy of antiviral therapy in patients with hepatitis B-related primary liver cancer
    Sun, Xifeng
    Yan, Xiaoyan
    Shao, Rongfeng
    Pan, Feng
    Li, Tingting
    Tian, Qinglian
    JOURNAL OF BUON, 2021, 26 (03): : 897 - 903
  • [43] Transcatheter Arterial Chemoembolization Therapy for Patients With Unresectable Hepatocellular Carcinoma
    Firouznia, Kavous
    Ghanaati, Hossein
    Alavian, Seyed Moayed
    Azadeh, Payam
    Toosi, Mohsen Nasiri
    Mirzaian, Arya Haj
    Najafi, Safa
    Shakiba, Madjid
    Jalali, Amir Hossein
    HEPATITIS MONTHLY, 2014, 14 (12) : e25792
  • [44] Therapy-related myeloid neoplasms after transcatheter arterial chemoembolization for hepatocellular carcinoma
    Yi, Jun Ho
    Jang, Jun Ho
    Jung, Chul Won
    BLOOD RESEARCH, 2021, 56 (04) : 349 - 353
  • [45] The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma
    Jiang, Enze
    Shangguan, Anna Junjie
    Chen, Shuangshuang
    Tang, Lin
    Zhao, Shuang
    Yu, Zhenghong
    CANCER LETTERS, 2016, 379 (02) : 262 - 267
  • [46] Evaluation of the efficacy of aparatinib and carrilizumab combined with transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma
    Chen, C.
    Duan, X. -T.
    LI, G. -Y.
    Hao, X. -J.
    Wang, W. -L.
    Shen, Y. -F.
    Zhang, S. -H.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (09) : 4135 - 4144
  • [47] Investigation of the efficacy on transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: meta-analysis
    Cho, W.
    Chen, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 393 - 394
  • [48] The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization
    Kim, Pyeong Hwa
    Gwon, Dong Il
    Kim, Jong Woo
    Chu, Hee Ho
    Kim, Jin Hyoung
    EUROPEAN RADIOLOGY, 2020, 30 (10) : 5650 - 5662
  • [49] The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization
    Pyeong Hwa Kim
    Dong Il Gwon
    Jong Woo Kim
    Hee Ho Chu
    Jin Hyoung Kim
    European Radiology, 2020, 30 : 5650 - 5662
  • [50] The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma
    Cho, Ju-Yeon
    Paik, Yong-Han
    Park, Hee Chul
    Yu, Jeong Il
    Sohn, Won
    Gwak, Geum-Youn
    Choi, Moon Seok
    Lee, Joon Hyeok
    Koh, Kwang Cheol
    Paik, Seung Woon
    Yoo, Byung Chul
    LIVER INTERNATIONAL, 2014, 34 (05) : 795 - 801